PharmaVoice

Stay informed with the latest pharma industry news and insights by signing up for PharmaVoice. Explore all our free newsletter options here: https://lnkd.in/gP2m_c7J

Just two years ago, there were no vaccines approved to prevent respiratory syncytial virus — now there are three RSV shots in circulation. And this week, The FDA accepted Merck & Co.’s biologics license application for the monoclonal antibody clesrovimab, which works differently from a vaccine but also provides protection against #RSV. https://lnkd.in/e4b23y3j

Eli Lilly and Company’s recently announced plan to partner with digital health company Ro on its LillyDirect platform marks a new turning point in the direct-to-consumer push among Big Pharma companies. #pharma #obesity #glp1 https://lnkd.in/g9y9ZmdH

Maternal mortality in the U.S. has been on the rise, increasing 144% from the first decade of the 2000s to the second. And experts are asking: What can the pharma industry do to protect mothers across the board? “If you compare this to innovations in other areas like chronic diseases, it’s really tiny in terms of the number of solutions we have," says Ahmet Metin Gülmezoglu, executive director at the nonprofit Concept Foundation (non-profit) Merck #maternalhealth Jacquelyn Caglia https://lnkd.in/eTm2ijvK

While biotechs look to hitch a ride on the GLP-1 weight loss rocket ship that shot drugs like Wegovy and Zepbound toward stratospheric sales, some of the contenders have gotten a swift gravity check. Here’s a look at three washouts in the drug development arena from Roche's Genentech, AbbVie and Cassava Sciences. #pharma #drugdevelopment #clinicaltrials https://lnkd.in/eQYPs7eX

Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics. “Put aside social justice — diversity is just good science," says Xoli Belgrave, Senior director, head, clinical trial diversity at Parexel. #diversity #pharma Kim Ribeiro Inside Edge Consulting Group Monique Adams, Ph.D. Sanofi https://lnkd.in/g6BfF89M

At this year’s American Society of Hematology conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases. “We are very excited with what we have at hand, and I’m super busy,” says Dr. L. Andres Sirulnik, senior vice president of translational and clinical sciences in hematology at Regeneron. https://lnkd.in/e5qqZP5B

The FDA has yet to make a decision about keeping tirzepatide on or off of its shortage list — letting compound pharmacies continue their lucrative operations for now. Manuel Jurado The Dedham Group Foley & Lardner LLP Nathan Beaver #GLP1 #pharma https://lnkd.in/eqeBKMSz

Just over a year ago, 23andMe’s co-founder and CEO Anne Wojcicki was assuring the life sciences industry that the company was a “full-fledged biotech” committed to drug R&D. Fast forward 13 months and the picture has changed dramatically for the battered company. https://lnkd.in/eGJbmUyn

GSK’s cancer drug #Blenrep failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could change the tide. “I reflect on this a lot, and this journey has been one of those unique experiences that drug developers don’t often go on,” says Dr.Hesham A. Abdullah, MD, MSc, global head of oncology R&D at GSK. https://lnkd.in/enMZbkjA